Pfizer's Exuberant Ad Rollout

Pfizer has launched a huge marketing campaign for slow-selling Exubera. Can it inject life into its needle-free insulin drug?

When Pfizer (PFE) introduced Exubera, the first ever inhalable insulin product for people with diabetes, the New York-based drug giant estimated it would be a $2 billion-a-year blockbuster. On July 18, a full year after launching Exubera, Pfizer disclosed the product's quarterly sales for the first time: An anemic $4 million. Now the company has debuted a massive ad campaign that some on Wall Street are calling a Hail Mary pass to jump-start Exubera sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.